Aminoflavone induces oxidative DNA damage and reactive oxidative species-mediated apoptosis in breast cancer cells

International Journal of Cancer

Volumn 122, Issue 7, 2008, Pages 1665-1674

  McLean, Lancelot ^a   Soto, Ubaldo ^a   Agama, Keli ^b   Francis, Jawad ^a   Jimenez, Randi ^a   Pommier, Yves ^b   Sowers, Lawrence ^a   Brantley, Eileen ^a  

^a LOMA LINDA UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Aminoflavone; Apoptosis; Breast cancer; DNA damage; Oxidative stress

Indexed keywords

5 AMINO 6,8 DIFLUORO 2 (3 FLUOROPHENYL) 7 METHYL 4H 1 BENZOPYRAN 4 ONE; 8 HYDROXYGUANINE; ACETYLCYSTEINE; ALPHA NAPHTHOFLAVONE; AMINOFLAVONE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; AROMATIC HYDROCARBON RECEPTOR; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; DNA; ESTROGEN RECEPTOR; GAMMA HISTONE H2AX; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; CASPASE; FLAVONOID; SCAVENGER;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL STRAIN MCF 7; CLINICAL EVALUATION; CONTROLLED STUDY; CROSS LINKING; DNA DAMAGE; DRUG CYTOTOXICITY; ENZYME ACTIVATION; ENZYME DEGRADATION; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; BREAST TUMOR; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENETICS; METABOLISM; PATHOLOGY; WESTERN BLOTTING;

ACETYLCYSTEINE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CASPASES; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; DNA DAMAGE; DNA, NEOPLASM; ENZYME ACTIVATION; FEMALE; FLAVONOIDS; FREE RADICAL SCAVENGERS; HUMANS; REACTIVE OXYGEN SPECIES; RECEPTORS, ESTROGEN; S PHASE;

EID: 39649102145     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23244     Document Type: Article

References (45)

1. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005;23:9312-18.
2. Stearns V, Davidson NE, Flockhart DA. Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J 2004;4:143-53.
3. Akama T, Shida Y, Sugaya T, Ishida H, Gomi K, Kasai M. Novel 5-aminoflavone derivatives as specific antitumor agents in breast cancer. J Med Chem 1996;39:3461-9.
4. Akama T, Ishida H, Shida Y, Kimura U, Gomi K, Saito H, Fuse E, Kobayashi S, Yoda N, Kasai M. Design and synthesis of potent antitumor 5,4′-diaminoflavone derivatives based on metabolic considerations. J Med Chem 1997;40:1894-900.
5. Akama T, Ishida H, Kimura U, Gomi K, Saito H. Structure-activity relationships of the 7-substituents of 5,4′-diamino-6,8,3′- trifluoroflavone, a potent antitumor agent. J Med Chem 1998;41:2056-67.
6. Loaiza-Perez AI, Kenney S, Boswell J, Hollingshead M, Alley MC, Hose C, Ciolino HP, Yeh GC, Trepel JB, Vistica DT, Sausville EA. Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells. Mol Cancer Ther 2004;3:715-25.
7. Kuffel MJ, Schroeder JC, Pobst LJ, Naylor S, Reid JM, Kaufmann SH, Ames MM. Activation of the antitumor agent aminoflavone (NSC 686288) is mediated by induction of tumor cell cytochrome P450 1A1/1A2. Mol Pharmacol 2002;62:143-53.
8. Meng LH, Kohlhagen G, Liao ZY, Antony S, Sausville E, Pommier Y. DNA-protein cross-links and replication-dependent histone H2AX phosphorylation induced by aminoflavone (NSC 686288), a novel anticancer agent active against human breast cancer cells. Cancer Res 2005;65:5337-43.
9. Pobst LJ, Ames MM. CYP1A1 activation of aminoflavone leads to DNA damage in human tumor cell lines. Cancer Chemother Pharmacol 2006;57:569-76.
10. Meng LH, Shankavaram U, Chen C, Agama K, Fu HQ, Gonzalez FJ, Weinstein J, Pommier Y. Activation of aminoflavone (NSC 686288) by a sulfotransferase is required for the antiproliferative effect of the drug and for induction of histone γ-H2AX. Cancer Res 2006;66:9656-64.
11. Chen C, Meng L, Ma X, Krausz KW, Pommier Y, Idle JR, Gonzalez FJ. Urinary metabolite profiling reveals CYP1A2-mediated metabolism of NSC686288 (aminoflavone). J Pharmacol Exp Ther 2006;318:1330-42.
12. Meng LH, Kohn KW, Pommier Y. Dose-response transition from cell cycle arrest to apoptosis with selective degradation of Mdm2 and p21(WAF1/CIP1) in response to the novel anticancer agent, aminoflavone (NSC 686288). Oncogene 2007;26:4806-16.
13. Pasqualini JR. Steroid sulphotransferase activity in human hormone-independent MDA-MB-468 mammary cancer cells. Eur J Cancer 1992;28A:758-62.
14. Lin J, Jin X, Rothman K, Lin HJ, Tang H, Burke W. Modulation of signal transducer and activator of transcription 3 activities by p53 tumor suppressor in breast cancer cells. Cancer Res 2002;62:376-80.
15. Bartek J, Iggo R, Gannon J, Lane DP. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990;5:893-9.
16. Yaginuma Y, Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 1992;52:4196-9.
17. Dotto GP. p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 2000;1471:M43-M56.
18. Vermeulen K, Van Bockstaele DR, Berneman ZN. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 2003;36:131-49.
19. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
20. Akashi M, Osawa Y, Koeffler HP, Hachiya M. p21WAF1 expression by an activator of protein kinase C is regulated mainly at the post-transcriptional level in cells lacking p53: important role of RNA stabilization. Biochem J 1999;337 (Part 3):607-16.
21. Gartel AL, Tyner AL. Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res 1999;246:280-9.
22. Zeng YX, el-Deiry WS. Regulation of p21WAF1/CIP1 expression by p53-independent pathways. Oncogene 1996;12:1557-64.
23. Kivinen L, Tsubari M, Haapajarvi T, Datto MB, Wang XF, Laiho M. Ras induces p21Cip1/Waf1 cyclin kinase inhibitor transcriptionally through Sp1-binding sites. Oncogene 1999;18:6252-61.
24. Esposito F, Russo L, Chirico G, Ammendola R, Russo T, Cimino F. Regulation of p21waf1/cip1 expression by intracellular redox conditions. IUBMB Life 2001;52:67-70.
25. Azam S, Hadi N, Khan NU, Hadi SM. Prooxidant property of green tea polyphenols epicatechin and epigallocatechin-3-gallate: implications for anticancer properties. Toxicol In Vitro 2004;18:555-61.
26. Bhat SH, Azmi AS, Hadi SM. Prooxidant DNA breakage induced by caffeic acid in human peripheral lymphocytes: involvement of endogenous copper and a putative mechanism for anticancer properties. Toxicol Appl Pharmacol 2007;218:249-55.
27. Johnson DE, Ochieng J, Evans SL. Phenylacetic acid halides inhibit estrogen receptor (ER)-positive MCF-7 cells, but not ER-negative human breast cancer cells or normal breast epithelial cells. Anticancer Drugs 1996;7:288-92.
28. Carrasco RA, Stamm NB, Patel BK. One-step cellular caspase-3/7 assay. Biotechniques 2003;34:1064-7.
29. Weinstein JN, Myers TG, O'Connor PM, Friend SH, Fornace AJ, Jr, Kohn KW, Fojo T, Bates SE, Rubinstein LV, Anderson NL, Buolamwini JK, van Osdol WW, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997;275:343-9.
30. Shao RG, Cao CX, Shimizu T, O'Connor PM, Kohn KW, Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 1997;57:4029-35.
31. Shigenaga MK, Aboujaoude EN, Chen Q, Ames BN. Assays of oxidative DNA damage biomarkers 8-oxo-2′-deoxyguanosine and 8-oxoguanine in nuclear DNA and biological fluids by high-performance liquid chromatography with electrochemical detection. Methods Enzymol 1994;234:16-33.
32. Kohn KW. DNA filter elution: a window on DNA damage in mammalian cells. Bioessays 1996;18:505-13.
33. Carmody RJ, Cotter TG. Signalling apoptosis: a radical approach. Redox Rep 2001;6:77-90.
34. Evans MD, Dizdaroglu M, Cooke MS. Oxidative DNA damage and disease: induction, repair and significance. Mutat Res 2004;567:1-61.
35. Klungland A, Bjelland S. Oxidative damage to purines in DNA: Role of mammalian Ogg1. DNA Repair (Amst) 2007;6:481-8.
36. Caldon CE, Daly RJ, Sutherland RL, Musgrove EA. Cell cycle control in breast cancer cells. J Cell Biochem 2006;97:261-74.
37. Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 2003;60:6-20.
38. Ueda S, Masutani H, Nakamura H, Tanaka T, Ueno M, Yodoi J. Redox control of cell death. Antioxid Redox Signal 2002;4:405-14.
39. Kang DH. Oxidative stress, DNA damage, and breast cancer. AACN Clin Issues 2002;13:540-9.
40. Lee-Hilz YY, Boerboom AM, Westphal AH, Berkel WJ, Aarts JM, Rietjens IM. Pro-oxidant activity of flavonoids induces EpRE-mediated gene expression. Chem Res Toxicol 2006;19:1499-505.
41. King RS, Ghosh AA, Wu J. Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab 2006;7:745-53.
42. Painter RB. Inhibition of mammalian cell DNA synthesis by ionizing radiation. Int J Radiat Biol Relat Stud Phys Chem Med 1986;49:771-81.
43. Paulovich AG, Hartwell LH. A checkpoint regulates the rate of progression through S phase in S. cerevisiae in response to DNA damage. Cell 1995;82:841-7.
44. Mobley JA, Brueggemeier RW. Increasing the DNA damage threshold in breast cancer cells. Toxicol Appl Pharmacol 2002;180:219-26.
45. Barker S, Weinfeld M, Murray D. DNA-protein crosslinks: their induction, repair, and biological consequences. Mutat Res 2005;589:111-35.